Details for Patent: 7,041,680

Title:	(R) and (S) isomers of substituted 2-(2,6-dioxopiperidin-3-yl) phthalimides and 1-oxoisoindolines and methods of using the same
Abstract:	Substituted 2-(2,6-dioxopiperidin-3-yl) phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl) isoindolines reduce the levels of TNF.alpha. in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline and 1,3-dioxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-aminoisoindoline.
Inventor(s):	Muller; George W. (Bridgewater, NJ), Stirling; David I. (Branchburg, NJ), Chen; Roger Shen-Chu (Edison, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Filing Date:	Apr 10, 2002
Application Number:	10/119,486
Claims:	1. A pharmaceutical composition comprising a therapeutically effective amount of the (S)-isomer of a compound of the formula: ##STR00007## or an acid addition salt of said isomer, wherein the (S) isomer is substantially free of its (R) isomer, in combination with a pharmaceutically and physiologically suitable carrier. 2. A single unit dosage form of the pharmaceutical composition according to claim 1, wherein the dosage form is a powder, tablet, capsule or an injectable composition. 3. A pharmaceutical composition comprising a therapeutically effective amount of the (R)-isomer of a compound of the formula: ##STR00008## or an acid addition salt of said isomer, wherein the (R) isomer is substantially free of its (S) isomer, in combination with a pharmaceutically and physiologically suitable carrier. 4. A single unit dosage form of the pharmaceutical composition according to claim 3, wherein the dosage form is as a powder, tablet, capsule or an injectable composition. 5. The pharmaceutical composition of claim 1, wherein the (S) isomer has an optical purity of greater than 95%. 6. The pharmaceutical composition of claim 3, wherein the (R) isomer has an optical purity of greater than 95%. 7. The pharmaceutical composition of claim 1, wherein the composition is suitable for parenteral administration. 8. The pharmaceutical composition of claim 7, which is a composition suitable for intravenous administration. 9. The pharmaceutical composition of claim 7, which comprises a sterile injectable solution. 10. The pharmaceutical composition of claim 3, wherein the composition is suitable for parenteral administration. 11. The pharmaceutical composition of claim 10, which is a composition suitable for intravenous administration. 12. The pharmaceutical composition of claim 10, which comprises a sterile injectable solution.